Nyrada Inc Share Price and Company Fundamentals
Last traded: Last Friday at 5:47 AM
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; NYR-BI01, a neuroprotectant drug, to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney for advancement of preclinical neuroprotection compound for traumatic brain injury. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
|Primary activities||Drug research and development|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||828 Pacific Highway Suite 2 Level 3 Gordon NSW 2072 Australia|
|Phone / Fax||61 2 9053 1990 / 61 2 9053 1999|
|Share registry||AUTOMIC REGISTRY SERVICES|
Nyrada Inc does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Nyrada Inc.
|Mr. James Bonnar||Chief Exec. Officer||319.29k|
|Mr. Cameron Jones C.A.||Chief Financial Officer|
|Mr. Benjamin Evison Ph.D.||Chief Scientific Officer|
|Ms. Laura Vize||Investor Relations Mang.|
|Mr. Mark Waring B.Sc., P.M.P.||Sr. VP of US Operations|
|Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.||Company Sec.||50|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Nyrada Inc is 39.78M and its enterprise value is 17.59M. The enterprise value to revenue ratio of NYR is 7.53.
Companies similar to Nyrada Inc (NYR)
Nyrada Inc (ASX:NYR) Frequently Asked Questions
1. What is Nyrada Inc's Stock Symbol?
Nyrada Inc trades on ASX under the ticker symbol "NYR".
2. What is Nyrada Inc's stock price today?
One share of NYR stock can currently be purchased for approximately $0.255.
3. How can I contact Nyrada Inc?
Nyrada Inc's mailing address is 828 Pacific Highway Suite 2 Level 3 Gordon NSW 2072 Australia. The company can be reached via phone at 61 2 9053 1990.
4. What is Nyrada Inc's official website?
The official website of Nyrada Inc is http://www.nyrada.com.
5. Which share registry manages Nyrada Inc's stock?
Nyrada Inc's stock is managed by AUTOMIC REGISTRY SERVICES.